Astrazeneca (AZN) to Release Quarterly Earnings on Monday

Astrazeneca (NYSE:AZN) is expected to be issuing its Q2 2026 results before the market opens on Monday, July 27th. Analysts expect the company to announce earnings of $2.10 per share and revenue of $15.4445 billion for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, July 27, 2026 at 6:45 AM ET.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, analysts expect Astrazeneca to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Astrazeneca Stock Up 0.2%

Shares of AZN opened at $168.68 on Friday. Astrazeneca has a 12 month low of $142.98 and a 12 month high of $212.71. The stock has a market cap of $261.61 billion, a price-to-earnings ratio of 25.33, a P/E/G ratio of 1.37 and a beta of 0.24. The company has a 50-day moving average price of $180.55 and a two-hundred day moving average price of $187.97. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Institutional Investors Weigh In On Astrazeneca

Several institutional investors have recently made changes to their positions in AZN. Triumph Capital Management acquired a new position in shares of Astrazeneca during the third quarter valued at about $25,000. JPL Wealth Management LLC bought a new stake in Astrazeneca in the 3rd quarter worth about $35,000. Johnson Financial Group Inc. increased its position in shares of Astrazeneca by 1,265.0% during the third quarter. Johnson Financial Group Inc. now owns 546 shares of the company’s stock valued at $42,000 after acquiring an additional 506 shares during the last quarter. Acumen Wealth Advisors LLC bought a new stake in shares of Astrazeneca during the 4th quarter worth $47,000. Finally, Binnacle Investments Inc raised its stake in shares of Astrazeneca by 21.8% during the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after purchasing an additional 118 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the company. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.